$Immunic (IMUX.US)$ The issue is they really have no product...

$Immunic (IMUX.US)$ The issue is they really have no product with final data while competitors move in with therapies that are FDA approved. The market for MS has many approved therapies. With each therapy approved, there is no immediate need for another one. Typically, this extends the approval time period. Even if data is very positive May of 2025 it will take 6 to 12 months for FDA to approve. So you will not see any real significant moves on this until 2026. By that time, they will need more capital. If by stock sale it is dilutive. Capital raise using debt increases risk of having to make an unfavorable deal to deal with creditors. Still below usd 2.00 this has great risk/reward proposition. Just requires risk taking. Good luck. Personally I have acquired a significant position in this stock. With existing data and safety profiles, this therapy should eclipse existing MS therapies becoming a blockbuster opportunity.